COVID-19 is caused by the novel Coronavirus, SARS-CoV-2, and has been spreading rapidly.
Although over 100 vaccines and numerous therapies are under development, their efficacy
is uncertain.
Importantly, SARS-CoV-2 is evolving rapidly with genetic mutations that may further impede
the efficacy of potential vaccines and therapies. A more virulent strain could also cause a
second wave of infections, even in those patients who may have previously had the disease.
Mapping the genetic variations between the isolates/strains and predicting the immune
responses of patients are vital to understanding strain-virulence, disease-spread, and
resistance against vaccines and therapies.
SARS-CoV-2: Sequencing & Characterization
20+ purpose-built and validated genomic algorithms are available to enable the sequencing and characterization of the SARS-CoV-2 isolates: assemble viral genomes, detect novel mutations and assess phylogenetic differences.
T/B-Cell Receptor Sequencing
The ability of COVID-19 patients to develop antibodies and natural immunity against the virus is limited in those with severe/fatal disease. Our B-Cell/T-Cell receptor repertoire sequencing analysis allows scientists to screen patients pre/post-vaccination or during therapy to uncover COVID-19 immunity or disease progression
Molecular drug targets: Review & Validation
Our Svastia platform has offered screening and validation of drug targets in oncology for pharmaceutical customers for over three years. We have utilized our in-house expertise and resources to identify and analyze drug targets for COVID-19. We are proud to be making the preliminary report freely available upon request.
Indian Institute of Technology (Madras)
Our Address
814 Mission Street, 6th Floor, San Francisco, CA 94103
Future Business Centre, Kings Hedges Road, Cambridge CB4 2HY
Call Us
m: +44 785 319 8595 (UK)